Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prophylaxis: Diphtheria, tetanus and pertussis · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Prophylaxis: Diphtheria, tetanus and pertussis | BIOLOGICAL | - |
Inclusion Criteria: \- Subjects previously enrolled and vaccinated in GSK Biologicals' studies APV-118 and APV-120 and who were 9 through 13 years of age Exclusion Criteria: * Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the a...
The GSK Tdap candidate vaccine is used as a booster, or sixth dose, to prevent acellular pertussis, diphtheria, and tetanus in children and adolescents previously vaccinated with five doses of an acellular pertussis-containing vaccine. It is being developed by GSK plc for the infectious disease indication of acellular pertussis.
GSK plc, traded under the ticker GSK, is developing the Tdap candidate vaccine. The vaccine is intended as a booster dose against acellular pertussis, diphtheria, and tetanus for children and adolescents who have already received five doses of an acellular pertussis-containing vaccine.
The GSK Tdap candidate vaccine is in Phase 3 clinical development. It is an investigational vaccine, not yet approved, being studied as a booster dose for children and adolescents previously vaccinated against acellular pertussis, diphtheria, and tetanus.
The GSK Tdap candidate vaccine has one completed Phase 3 trial, NCT00263679, which assessed its immunogenicity and safety as a sixth booster dose in children and adolescents in Germany. The trial enrolled 321 participants aged 9 years and older, was randomized and double-blind, and has been completed.
The GSK Tdap candidate vaccine is a booster vaccine targeting acellular pertussis, diphtheria, and tetanus, similar to other Tdap vaccines. However, it is specifically being studied as a sixth dose in individuals previously vaccinated with five doses of an acellular pertussis-containing vaccine, and it is still in clinical development.